Olysio is an anti-hepatitis C drug owned by Janssen Prods. The drug's active ingredient is simeprevir sodium and it was first authorized for market use on 22 November, 2013. Olysio has a total of 9 drug patents, none of which have expired yet.
The generics of Olysio are expected to be released after the 05th of September, 2029. This is when the last patent for Olysio, US8148399 titled 'Macrocyclic inhibitors of hepatitis C virus,' expires.
Olysio is primarily used in the treatment of hepatitis C. The drug's effectiveness is largely due to its active ingredient, simeprevir sodium, which helps inhibit the replication of the hepatitis C virus and manages the disease.
Olysio holds nine patents with the latest one, patent US8148399 titled 'Macrocyclic inhibitors of hepatitis C virus,' set to expire on the 05th of September, 2029. This would subsequently allow for the release of the Olysio generic. Below are the details of the patent: